There is a compound that has been introduced as an active component of a drug component, such as a drug component for the treatment of chronic renal failure and / or diabetic nephropathy. The anticompetitive compounds of EP4 receptor have been studied extensively. It is found that an anhydride compound or its salt shows the anticompetitive effect of EP4 receptor,In this way, we can finish the task now Ammonia compounds or their salts have an antagonistic effect on EP4 receptor and can be used as active components of a pharmaceutical component to prevent and / or treat various EP4 related diseases, such as chronic renal failure and / or diabetic nephropathy. 1:4 - [(1s) - 1 - ([4-bromo-1 - (isomethyl-3-methyl) - 3-methyl-1h-pyrazol-5-one) carbonil} amino) ethyl] benzoic acid or a salt is required. 3. Requirement 3: Compound conforming to requirement 2,This is a glass of 4 - [(1s) - 1 - ([4-bromo-1 - (isomethyl-3-methyl) - 3-methyl-1h-pyrazol-5-ii) carbonil} amino) ethyl) benzoic acid. Requirement 4: Compound meeting the requirements of item 3, X-ray powder diffraction method using Cu as conduit, which is a glass with a thermal peak starting temperature of 2q (o) in 192c DSC analysis, equivalent to 4.7, 9.5, 12.0, 13.2, 13.7, 15.3, 18.8, 20.3, 20.9 and 22.8.Se presenta un compuesto que es útil como ingrediente activo de una composición farmacéutica, por ejemplo, una composición farmacéutica para tratar la insuficiencia renal crónica y/o la nefropatía diabética. Se han llevado a cabo extensos estudios sobre un compuesto con una acción antagonista del receptor EP4 y han encontrado que un compuesto amídico o una sal del mismo exhibe una acción antagonista del receptor EP4, completando de esa manera la presente. El compuesto amídico o una sal del mismo tiene acción antagonista del receptor EP4 y se lo puede utilizar como ingrediente activo de una composición farmacéutica para prevenir y/o tratar diversas enfermedades relacionadas con el EP4, por ejemplo, la insuficiencia
